Stock Analysis of CureVac NV (CVAC) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code CVAC
Close 3.48
Change -0.190 / 5.18 %
Volume 763103
Vol Change -411268.00 / 35.02 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of CureVac NV
PE (TTM)

-2.71

Very Poor
Price / Book

1.30

Good
Price / Sales

11.36

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

780584 K

Enterprise Value

382810 K

ROA (TTM)

-33.45

Very Poor
ROE (TTM)

-47.88

Very Poor
Net Margin (TTM)

-418.52

Very Poor
Revenue

36.40 %

42880.00 K
Net Profit

21.39 %

-302298.00 K
Debt to Equity

0.0097

Excellent
Altman Z Score

-1.83

Very Poor
Quick Ratio

2.43

Good
Cash Ratio

2.16

Good


Highs/Lows of CureVac NV
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week4.59 24.18 % 2.10 % 4.583.4312-Jun-2417-Jun-24
Two Week4.34 19.82 % 3.59 % 5.283.4306-Jun-2417-Jun-24
One Month3.49 0.287 % 3.20 % 5.283.2506-Jun-2421-May-24
Three Month3.3 5.45 % 6.96 % 5.282.21506-Jun-2425-Apr-24
Six Months6.12 43.14 % 15.98 % 6.232.21518-Dec-2325-Apr-24
One year10.24 66.02 % 24.12 % 12.362.21523-Jun-2325-Apr-24
Two year14.27 75.61 % 48.94 % 12.792.21511-Jan-2325-Apr-24


Technical View of CureVac NV
RSI

44.43

Neutral
MACD

0.185

Mild Bearish
ADX

38.55

Mild Bullish
Super Trend

4.77

Bearish
Williams %R

-97.30

Mild Bearish
CCI

-97.69

Neutral


EMA 5

3.85

Strong Bearish
EMA 15

3.97

Strong Bearish
EMA 50

3.58

Strong Bearish
EMA 100

3.70

Neutral
SMA 100

3.31

Mild Bullish
SMA 200

4.51

Mild Bearish
SMA 5 / 20

3.91 / 4.00

Strong Bearish
SMA 15 / 50

4.11 / 3.29

Strong Bullish
SMA 50 / 200

3.29 / 4.51

Mild Bearish




Charts of CureVac NV


Returns of CureVac NV with Peers
Period / StockCVACAUPHIMNMLAB
1 Week-24.18%2.59%-18.07%-12.45%
1 Mth-0.287%-3.82%-4.92%-17.90%
3 Mth5.45%7.16%-41.50%-19.47%
6mth-43.14%-41.00%74.40%6.03%
1 Year-66.02%-42.47%127.12%-1.40%
2 Year-75.61%-47.88%417.72%15.93%
5 Years--12.62%--83.09%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of CureVac NV with Peers
Ratio / StockCVACAUPHIMNMLAB
PE-2.71-12.68-1.69-6.38
P/B1.302.064.511.05
ROA-33.45-11.85-178.21-10.14
ROE-47.88-16.23-266.86-21.53
Debt To Equity0.00970.04130.00260.416
Revenue42880.00 K
36.40 % 		158853 K
18.52 % 		10192.00 K
53.80 % 		105173 K
7.38 %
Net Income-302298.00 K
21.39 % 		-77191.00 K
28.65 % 		-21958.00 K
41.47 % 		-75725.00 K
60.17 %


Technicals of CureVac NV with Peers
Technical / StockCVACAUPHIMNMLAB-
ADX38.5528.0217.7418.21
CMF-0.070-0.063-0.322-0.176
MFI57.1971.3245.5635.24
RSI44.4355.0235.0229.85
MACD Abv SignalFalseTrueTrueFalse
Price Above 50 MATrueTrueFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : CureVac NV

Address : Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076
Tel : 49 7071 9883 0
URL : https://www.curevac.com
Code : CVAC, ISIN : NL0015436031, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 14_Aug_2020
Employee Count : 999

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.


Note : All Data Generated at the End of Trading Hours (EOD Data)